These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 8297742

  • 21. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
    Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H, Schmitt M, German N0 Study Group.
    J Natl Cancer Inst; 2001 Jun 20; 93(12):913-20. PubMed ID: 11416112
    [Abstract] [Full Text] [Related]

  • 22. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA, Look MP, Peters HA, van Putten WL, Portengen H, Klijn JG.
    J Natl Cancer Inst; 1995 May 17; 87(10):751-6. PubMed ID: 7563153
    [Abstract] [Full Text] [Related]

  • 23. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer.
    Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H, Graeff H.
    Breast Cancer Res Treat; 1993 May 17; 24(3):195-208. PubMed ID: 8435475
    [Abstract] [Full Text] [Related]

  • 24. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
    Konecny G, Untch M, Arboleda J, Wilson C, Kahlert S, Boettcher B, Felber M, Beryt M, Lude S, Hepp H, Slamon D, Pegram M.
    Clin Cancer Res; 2001 Aug 17; 7(8):2448-57. PubMed ID: 11489825
    [Abstract] [Full Text] [Related]

  • 25. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.
    Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Fernö M, Eppenberger-Castori S, Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brünner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder ME, Manders P, Fiets WE, Blankenstein MA, Broët P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex LV, Klijn JG, O'Higgins N, Eppenberger U, Jänicke F, Schmitt M, Foekens JA.
    J Natl Cancer Inst; 2002 Jan 16; 94(2):116-28. PubMed ID: 11792750
    [Abstract] [Full Text] [Related]

  • 26. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
    Grøndahl-Hansen J, Christensen IJ, Briand P, Pappot H, Mouridsen HT, Blichert-Toft M, Danø K, Brünner N.
    Clin Cancer Res; 1997 Feb 16; 3(2):233-9. PubMed ID: 9815678
    [Abstract] [Full Text] [Related]

  • 27. Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients.
    de Witte JH, Sweep CG, Klijn JG, Grebenschikov N, Peters HA, Look MP, van Tienoven TH, Heuvel JJ, van Putten WL, Benraad TJ, Foekens JA.
    Br J Cancer; 1999 Mar 16; 79(7-8):1190-8. PubMed ID: 10098758
    [Abstract] [Full Text] [Related]

  • 28. Plasminogen activator inhibitor type 2 in breast cancer.
    Duggan C, Kennedy S, Kramer MD, Barnes C, Elvin P, McDermott E, O'Higgins N, Duffy MJ.
    Br J Cancer; 1997 Mar 16; 76(5):622-7. PubMed ID: 9303361
    [Abstract] [Full Text] [Related]

  • 29. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.
    Nekarda H, Schmitt M, Ulm K, Wenninger A, Vogelsang H, Becker K, Roder JD, Fink U, Siewert JR.
    Cancer Res; 1994 Jun 01; 54(11):2900-7. PubMed ID: 8187075
    [Abstract] [Full Text] [Related]

  • 30. Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activator.
    Descotes F, Riche B, Saez S, De Laroche G, Datchary J, Roy P, André J, Bobin JY.
    Clin Breast Cancer; 2008 Apr 01; 8(2):168-77. PubMed ID: 18621614
    [Abstract] [Full Text] [Related]

  • 31. Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma.
    Gandolfo GM, Conti L, Vercillo M.
    Anticancer Res; 1996 Apr 01; 16(4B):2155-9. PubMed ID: 8694536
    [Abstract] [Full Text] [Related]

  • 32. [Breast cancer: prognostic value of a dissemination index based on 4 components of the urokinase-type plasminogen activator system].
    Bouchet C, Hacène K, Martin PM, Becette V, Tubiana-Hulin M, Lasry S, Oglobine J, Spyratos F.
    Pathol Biol (Paris); 2000 Nov 01; 48(9):825-31. PubMed ID: 11141918
    [Abstract] [Full Text] [Related]

  • 33. Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.
    Fuessel S, Erdmann K, Taubert H, Lohse-Fischer A, Zastrow S, Meinhardt M, Bluemke K, Hofbauer L, Fornara P, Wullich B, Baretton G, Magdolen V, Wirth MP, Kotzsch M.
    BMC Cancer; 2014 Dec 18; 14():974. PubMed ID: 25519168
    [Abstract] [Full Text] [Related]

  • 34. [The prognostic importance of urinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in the primary resection of oral squamous cell carcinoma].
    Hundsdorfer B, Zeilhofer HF, Bock KP, Dettmar P, Schmitt M, Horch HH.
    Mund Kiefer Gesichtschir; 2004 May 18; 8(3):173-9. PubMed ID: 15138855
    [Abstract] [Full Text] [Related]

  • 35. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system.
    Heiss MM, Babic R, Allgayer H, Gruetzner KU, Jauch KW, Loehrs U, Schildberg FW.
    J Clin Oncol; 1995 Aug 18; 13(8):2084-93. PubMed ID: 7636552
    [Abstract] [Full Text] [Related]

  • 36. [Plasminogen activator inhibitor 1 and prognosis in breast carcinoma].
    Mayerhofer K, Stolzlechner J, Yildiz S, Haider K, Heinzl H, Jakesz R, Pecherstorfer M, Rosen H, Sevelda P, Zeillinger R, Speiser P.
    Geburtshilfe Frauenheilkd; 1996 Jan 18; 56(1):23-7. PubMed ID: 8852782
    [Abstract] [Full Text] [Related]

  • 37. Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas.
    Fujii T, Obara T, Tanno S, Ura H, Kohgo Y.
    Hepatogastroenterology; 1999 Jan 18; 46(28):2299-308. PubMed ID: 10521987
    [Abstract] [Full Text] [Related]

  • 38. [Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx].
    Zhao EM, Han DM, Yu ZK, Fan EZ, Li Y.
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Feb 18; 38(1):39-42. PubMed ID: 12778766
    [Abstract] [Full Text] [Related]

  • 39. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
    Hundsdorfer B, Zeilhofer HF, Bock KP, Dettmar P, Schmitt M, Kolk A, Pautke C, Horch HH.
    J Craniomaxillofac Surg; 2005 Jun 18; 33(3):191-6. PubMed ID: 15878520
    [Abstract] [Full Text] [Related]

  • 40. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.
    Offersen BV, Pfeiffer P, Andreasen P, Overgaard J.
    Lung Cancer; 2007 Apr 18; 56(1):43-50. PubMed ID: 17207889
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.